Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $5.9 million.

  • Heron Therapeutics' Other Non-Current Assets fell 12.30% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 12.30%. This contributed to the annual value of $6.5 million for FY2024, which is 20.24% down from last year.
  • Latest data reveals that Heron Therapeutics reported Other Non-Current Assets of $5.9 million as of Q3 2025, which was down 3.30% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Other Non-Current Assets peaked at $18.0 million during Q1 2022, and registered a low of $346,000 during Q1 2021.
  • In the last 3 years, Heron Therapeutics' Other Non-Current Assets had a median value of $6.9 million in 2024 and averaged $7.8 million.
  • Per our database at Business Quant, Heron Therapeutics' Other Non-Current Assets skyrocketed by 5,095.66% in 2022 and then crashed by 51.71% in 2023.
  • Heron Therapeutics' Other Non-Current Assets (Quarterly) stood at $17.7 million in 2021, then dropped by 11.34% to $15.7 million in 2022, then slumped by 48.27% to $8.1 million in 2023, then declined by 20.24% to $6.5 million in 2024, then dropped by 12.30% to $5.9 million in 2025.
  • Its Other Non-Current Assets stands at $5.9 million for Q3 2025, versus $6.1 million for Q2 2025 and $6.3 million for Q1 2025.